Complementarity-Determining Region 3 (CDR3) of the Heavy Chain Only Antibodies: Therapeutic Perspectives
, , y
27 jun 2024
Acerca de este artículo
Publicado en línea: 27 jun 2024
Páginas: 64 - 71
Recibido: 04 abr 2024
Aceptado: 21 may 2024
DOI: https://doi.org/10.2478/fv-2024-0019
Palabras clave
© 2024 Lea Talpašová et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Talpašová, Lea
Laboratory of Biomedical Microbiology and Immunology, University of Veterinary Medicine and Pharmacy in KošiceKošice
Bhide, Katarína
Laboratory of Biomedical Microbiology and Immunology, University of Veterinary Medicine and Pharmacy in KošiceKošice
Maľarik, Tomáš
Laboratory of Biomedical Microbiology and Immunology, University of Veterinary Medicine and Pharmacy in KošiceKošice
Bhide, Mangesh
Laboratory of Biomedical Microbiology and Immunology, University of Veterinary Medicine and Pharmacy in KošiceKošice
Institute of Neuroimmunology, Slovak Academy of Sciences v. v. i.Bratislava, Slovakia